FI116385B - (R)-(-)-2-[5-(4-fluorifenyyli)-3-pyridyyli-metyyliaminometyyli]kromaani keskushermoston sairauksien hoitoa varten - Google Patents

(R)-(-)-2-[5-(4-fluorifenyyli)-3-pyridyyli-metyyliaminometyyli]kromaani keskushermoston sairauksien hoitoa varten Download PDF

Info

Publication number
FI116385B
FI116385B FI954874A FI954874A FI116385B FI 116385 B FI116385 B FI 116385B FI 954874 A FI954874 A FI 954874A FI 954874 A FI954874 A FI 954874A FI 116385 B FI116385 B FI 116385B
Authority
FI
Finland
Prior art keywords
fluorophenyl
pyridylmethylaminomethyl
chroman
acid
salt
Prior art date
Application number
FI954874A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI954874A (fi
FI954874A0 (fi
Inventor
Henning Boettcher
Gerd Bartoszyk
Hartmut Greiner
Jean-Jacques Berthelon
Michel Brunet
Ralf Devant
Marc Noblet
Jean-Jacques Zeiller
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of FI954874A0 publication Critical patent/FI954874A0/fi
Publication of FI954874A publication Critical patent/FI954874A/fi
Application granted granted Critical
Publication of FI116385B publication Critical patent/FI116385B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
    • C07C217/14—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring
    • C07C217/16—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring not being further substituted
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
    • C07C217/14—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring
    • C07C217/18—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
    • C07C217/20—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted by halogen atoms, by trihalomethyl, nitro or nitroso groups, or by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/54—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/64—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with oxygen atoms directly attached in position 8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
FI954874A 1994-10-14 1995-10-13 (R)-(-)-2-[5-(4-fluorifenyyli)-3-pyridyyli-metyyliaminometyyli]kromaani keskushermoston sairauksien hoitoa varten FI116385B (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP94116223 1994-10-14
EP94116223 1994-10-14

Publications (3)

Publication Number Publication Date
FI954874A0 FI954874A0 (fi) 1995-10-13
FI954874A FI954874A (fi) 1996-04-15
FI116385B true FI116385B (fi) 2005-11-15

Family

ID=8216383

Family Applications (1)

Application Number Title Priority Date Filing Date
FI954874A FI116385B (fi) 1994-10-14 1995-10-13 (R)-(-)-2-[5-(4-fluorifenyyli)-3-pyridyyli-metyyliaminometyyli]kromaani keskushermoston sairauksien hoitoa varten

Country Status (27)

Country Link
US (1) US5767132A (ja)
EP (2) EP1123933A1 (ja)
JP (1) JP3880645B2 (ja)
KR (1) KR100389497B1 (ja)
CN (1) CN1246319C (ja)
AT (1) ATE210657T1 (ja)
AU (1) AU703637B2 (ja)
BR (1) BR9504379A (ja)
CA (1) CA2160447C (ja)
CO (1) CO4480021A1 (ja)
CZ (1) CZ292104B6 (ja)
DE (1) DE69524528T2 (ja)
DK (1) DK0707007T3 (ja)
ES (1) ES2169102T3 (ja)
FI (1) FI116385B (ja)
HU (1) HU227883B1 (ja)
MX (1) MX9504332A (ja)
NO (1) NO308848B1 (ja)
PL (1) PL181165B1 (ja)
PT (1) PT707007E (ja)
RU (1) RU2155753C2 (ja)
SI (1) SI0707007T1 (ja)
SK (1) SK283870B6 (ja)
TR (1) TR199501253A2 (ja)
TW (1) TW420664B (ja)
UA (1) UA45952C2 (ja)
ZA (1) ZA958673B (ja)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR004523A1 (es) * 1995-11-06 1998-12-16 American Home Prod 2-(AMINOMETIL)-3,4,7,9-TETRAHIDRO-2H-PIRANO-[2,3e] INDOL-8-ONAS Y COMPOSICIONES FARMACEUTICAS QUE LAS COMPRENDEN
CA2259927A1 (en) 1996-07-12 1998-01-22 Leukosite, Inc. Chemokine receptor antagonists and methods of use therefor
FR2756284B1 (fr) * 1996-11-26 2000-04-28 Adir Nouveaux derives du benzopyrane, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6127380A (en) * 1997-02-18 2000-10-03 American Home Products Corporation 4-aminoalkoxy-1H-benzoimidazoles
HUP0001311A3 (en) * 1997-02-18 2001-07-30 American Home Products Corp Ma 5-aminoalkoxy-1,4-dihydroquinoxaline-2,3-diones being dopamine agonists and pharmaceutical compositions containing them
US5990144A (en) * 1997-02-18 1999-11-23 American Home Products Corporation 4-aminoalkoxy-1,3-dihydrobenzoimidazol-2-one dopamine autoreceptor agonists
AU5915298A (en) * 1997-02-18 1998-09-08 American Home Products Corporation 4-aminoalkoxy-1,3-dihydrobenzoimidazol-2-thiones derivatives, their preparation and their use as dopamine autoreceptor (d2) agonists
IL131156A0 (en) * 1997-02-18 2001-01-28 American Home Prod 4-Aminoalkyl-1,3-dihydrobenzoimidazol-2-one derivatives their preparation and their use as dopamine autoreceptor (d2) agonists
US5922715A (en) * 1997-02-18 1999-07-13 American Home Products Corporation 5-aminoalkoxy-1, 4-dihydroquinoxaline-2, 3-diones
JP2001509814A (ja) * 1997-02-18 2001-07-24 アメリカン・ホーム・プロダクツ・コーポレイション ４−アミノアルコキシ−１ｈ−ベンゾイミダゾール誘導体、それらの調製およびそれらのドパミン自己受容体（ｄ▲下２▼）作動薬としての使用
US5972958A (en) * 1997-02-18 1999-10-26 American Home Products Corporation 4-aminoalkoxy-1,3-dihydro-benzoimidazol-2-thiones
CO5011067A1 (es) * 1997-11-03 2001-02-28 Novartis Ag Derivados de bifenilo como productos farmaceuticos, su pre- paracion y composiciones farmaceuticas que los contienen
US7189753B1 (en) 1997-11-06 2007-03-13 Cady Roger K Preemptive prophylaxis of migraine
FR2786767B1 (fr) * 1998-12-02 2001-02-23 Pf Medicament Nouveaux derives de 3-alkoxybenzylamines et leur utilisation a titre de medicaments pour le traitement de la schizophrenie
DE19858341A1 (de) 1998-12-17 2000-06-21 Merck Patent Gmbh Chromanderivate
AU3772800A (en) * 1999-03-24 2000-10-09 Sepracor, Inc. Diaryl thioethers, compositions and uses thereof
DE10005150A1 (de) * 2000-02-07 2001-08-09 Merck Patent Gmbh Verfahren zur Herstellung von 5-Arylnicotinaldehyden
GB0004152D0 (en) 2000-02-23 2000-04-12 Astrazeneca Uk Ltd Novel compounds
GB0004153D0 (en) 2000-02-23 2000-04-12 Astrazeneca Uk Ltd Novel use
GB0004151D0 (en) 2000-02-23 2000-04-12 Astrazeneca Uk Ltd Novel use
UA73981C2 (en) * 2000-03-10 2005-10-17 Merck Patent Gmbh (r)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane for treatment of extrapyramidal movement disorders (variants), pharmaceutical composition and kit
DE10029371A1 (de) * 2000-06-20 2002-01-03 Merck Patent Gmbh Heterocyclische Aminoalkylpyridinderivate als Psychopharmaka
DE10044091A1 (de) 2000-09-07 2002-04-04 Merck Patent Gmbh Chromanonderivate
RU2283648C2 (ru) * 2000-11-14 2006-09-20 Мерк Патент Гмбх Новое применение комбинированных селективных антагонистов допаминового рецептора d2 и агонистов рецептора 5-нт 1a
DE10120619A1 (de) * 2001-04-26 2002-10-31 Merck Patent Gmbh 2-(5-(4-Fluorphenyl)-3-pyridylmethylaminomethyl-chroman
DK1408964T3 (da) 2001-07-26 2007-05-21 Merck Patent Gmbh Hidtil ukendt anvendelse af 2-5-(4-fluorphenyl)-3-pyridylmethylaminomethyl-chroman og fysiologisk acceptable salte deraf
SE0102639D0 (sv) * 2001-07-31 2001-07-31 Astrazeneca Ab Novel compounds
SE0102640D0 (sv) * 2001-07-31 2001-07-31 Astrazeneca Ab Novel compounds
SE0102641D0 (sv) * 2001-07-31 2001-07-31 Astrazeneca Ab Novel compounds
WO2003024960A1 (en) * 2001-09-19 2003-03-27 Merck Patent Gmbh Novel use of substituted aminomethyl chromans
WO2003029239A1 (en) 2001-10-04 2003-04-10 Wyeth Chroman and benzofuran derivatives as 5-hydroxytryptamine-6 ligands
US20050014818A1 (en) * 2001-11-09 2005-01-20 Masaru Mitsuda Process for producing optically active chroman derivative and intermediate
GB0225548D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Compounds
US7728155B2 (en) 2003-10-24 2010-06-01 Wyeth Llc Dihydrobenzofuranyl alkanamines and methods for using same as cns agents
US20050261347A1 (en) * 2003-10-24 2005-11-24 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
US7435837B2 (en) * 2003-10-24 2008-10-14 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
BRPI0507670A (pt) 2004-02-13 2007-07-17 Warner Lambert Co moduladores do receptor de androgênio
EP1737813A1 (en) 2004-04-13 2007-01-03 Warner-Lambert Company LLC Androgen modulators
CA2562672C (en) 2004-04-22 2009-09-29 Warner-Lambert Company Llc 4-cyano-phenoxy derivatives as androgen modulators
JP4874965B2 (ja) 2004-07-08 2012-02-15 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー アンドロゲン調節剤
CA2605587A1 (en) * 2005-04-22 2006-11-02 Wyeth Chromane and chromene derivatives and uses thereof
GT200600158A (es) * 2005-04-22 2006-11-28 Cristales formados de clorhidrato de {[(2r)-7-(2,6-diclorofenil)-5-fluoro-2,3-dihidro-1-benzofurano-2-il]metil}amina
TW200724139A (en) 2005-05-05 2007-07-01 Warner Lambert Co Androgen modulators
TW200811182A (en) 2006-05-25 2008-03-01 Wyeth Corp Oxindoledioxans, synthesis thereof, and intermediates thereto
PL2699543T3 (pl) 2011-04-19 2016-10-31 Nowe modulatory mediowanego receptorem dopaminergicznym i nmda glutaminergicznego przekaźnictwa nerwowego zwojów korowych
US10577308B2 (en) * 2015-03-26 2020-03-03 The Florey Institute Sodium channel modulators

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2364685C3 (de) * 1973-12-27 1978-06-15 Beiersdorf Ag, 2000 Hamburg Phenoxyäthylamine
FR2397417A1 (fr) * 1977-07-12 1979-02-09 Parcor Procede de preparation de derives de la thienopyridine
JPS55124742A (en) * 1979-03-20 1980-09-26 Kyowa Hakko Kogyo Co Ltd Novel aminoalcohol derivative
CA1337429C (en) * 1983-12-05 1995-10-24 Guy Rosalia Eugene Van Lommen Derivatives of 2,2'-iminobisethanol
DE3901814A1 (de) * 1988-07-28 1990-02-01 Bayer Ag Substituierte aminomethylzetraline sowie ihre heterocyclischen analoga
DE4135474A1 (de) * 1991-10-28 1993-04-29 Bayer Ag 2-aminomethyl-chromane
SI9300097B (en) * 1992-02-27 2001-12-31 Janssen Pharmaceutica Nv (benzodioxan, benzofuran or benzopyran) alkylamino) alkyl substituted guanidines
JPH05255302A (ja) * 1992-03-09 1993-10-05 Yamanouchi Pharmaceut Co Ltd 新規なクロマニルオキシアルキルアミン誘導体
DE4226527A1 (de) * 1992-08-11 1994-02-17 Merck Patent Gmbh 1,4-Benzodioxanderivate
WO1995005383A1 (en) * 1993-08-19 1995-02-23 Janssen Pharmaceutica N.V. Vasocontrictive dihydrobenzopyran derivatives

Also Published As

Publication number Publication date
TR199501253A2 (tr) 1996-06-21
NO954080D0 (no) 1995-10-13
SI0707007T1 (en) 2002-04-30
CN1130180A (zh) 1996-09-04
CO4480021A1 (es) 1997-07-09
HU227883B1 (en) 2012-05-29
DE69524528D1 (de) 2002-01-24
MX9504332A (es) 1997-03-29
PT707007E (pt) 2002-06-28
FI954874A (fi) 1996-04-15
KR100389497B1 (ko) 2003-09-19
EP0707007B1 (en) 2001-12-12
PL181165B1 (pl) 2001-06-29
SK126695A3 (en) 1996-06-05
JP3880645B2 (ja) 2007-02-14
EP0707007A1 (en) 1996-04-17
KR960014123A (ko) 1996-05-22
AU703637B2 (en) 1999-03-25
NO308848B1 (no) 2000-11-06
CN1246319C (zh) 2006-03-22
ATE210657T1 (de) 2001-12-15
SK283870B6 (sk) 2004-03-02
US5767132A (en) 1998-06-16
BR9504379A (pt) 1997-05-27
RU2155753C2 (ru) 2000-09-10
DK0707007T3 (da) 2002-03-18
AU3421895A (en) 1996-04-26
UA45952C2 (uk) 2002-05-15
CA2160447C (en) 2008-09-02
EP1123933A1 (en) 2001-08-16
PL310932A1 (en) 1996-04-15
CA2160447A1 (en) 1996-04-15
ZA958673B (en) 1996-05-22
HU9502976D0 (en) 1995-12-28
FI954874A0 (fi) 1995-10-13
JPH08225501A (ja) 1996-09-03
ES2169102T3 (es) 2002-07-01
NO954080L (no) 1996-04-15
TW420664B (en) 2001-02-01
DE69524528T2 (de) 2002-08-01
CZ266195A3 (en) 1996-04-17
HUT75644A (en) 1997-05-28
CZ292104B6 (cs) 2003-07-16

Similar Documents

Publication Publication Date Title
FI116385B (fi) (R)-(-)-2-[5-(4-fluorifenyyli)-3-pyridyyli-metyyliaminometyyli]kromaani keskushermoston sairauksien hoitoa varten
JP4700017B2 (ja) ピペリジン類およびピペラジン類
JP4740115B2 (ja) 置換ピラゾール
US5723614A (en) Benzofurans
JP4059671B2 (ja) ベンズイミダゾール誘導体
US6310068B1 (en) Benzonitriles and benzofluorides
US20090291963A1 (en) Substituted indoles
JP2011153144A (ja) 置換ピラゾール化合物
JP4740116B2 (ja) 精神疾患および神経障害の処置のための５−ｈｔ受容体アンタゴニスト
JP4198183B2 (ja) 選択的ドーパミンｄ３アゴニストとしてのアミノピリジン誘導体
JP4833832B2 (ja) ピラゾール化合物
JP2002543079A (ja) うつ病治療用のアザインドール誘導体
AU2004226279B2 (en) Chromenone indoles
KR20030022390A (ko) ５-ｈｔａ１ 수용체 및/또는 도파민 ｄ２ 수용체와 관련된질병의 치료를 위한 크로메논 유도체 및 이의 용도
JP4563817B2 (ja) インドール誘導体およびその５−ｈｔ配位子としての使用
RU2379307C2 (ru) Соединение циклического амина
ES2304599T3 (es) Derivados de bencofurano y su empleo como antidepresivos y ansioliticos.
US7834032B2 (en) Piperidine derivatives
CN118019738A (zh) 作为sting拮抗剂的小分子脲衍生物

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 116385

Country of ref document: FI

MA Patent expired